Syncona, a life science investor focused on creating, building and scaling global leaders in life science, completed the acquisition of the remaining stake in Freeline Therapeutics, a clinical-stage biotechnology company, for $15m. "We continue to be excited by the data published by Freeline in its FLT201 programme and are pleased with how the company is executing. Our capital allocation is resolutely focused on opportunities with strong prospects of driving an asset to late-stage development, where we believe significant value can be accessed. The challenging market conditions impacting the biotech sector have presented a differentiated opportunity to deploy capital in line with that approach. The flexibility of the Syncona platform, enabled by our capital pool, allows us to optimise how we do this and, in this instance, taking the company private allows us the best route to potential risk-adjusted returns," Chris Hollowood, Syncona CEO.